FDA Approved: GLYXAMBI — Original Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

GLYXAMBI (empagliflozin and linagliptin) received FDA approval as a fixed-dose combination product for adults with Type 2 diabetes mellitus. It represents an or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GLYXAMBI (empagliflozin and linagliptin)

Snippet

ORIG AP for GLYXAMBI (EMPAGLIFLOZIN AND LINAGLIPTIN)